Skip to content
Home
Close Home
Open Home
Journal information
Editorial board
Operations manual
Editorial policies
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Close Read
Open Read
Archive
TOC Alert
Current issue
Information
Close Information
Open Information
Editorial & Peer Review
Ethical policies
Funding
Complaints and appeals
Open access and licensing
Authors
Sponsorship
Contact
Publish
Close Publish
Open Publish
Instructions to authors
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
Home
Journal Information
Editorial Board
Operations Manual
Editorial Polices
Code of conduct for authors
Code of conduct for reviewers
Ahead of print
Read
Archive
Toc Alert
Current issue
Information
Editorial & Peer review
Ethical policies
Funding
Procedure for complaints and/or appeals
Open access & Licensing
Authors
Sponsors
Contact
Publish
Authors Instructions
Online submission
ES
EN
0,00
€
0
Cart
TOC Alert
Hot News
A New Era for HIV-Specific T-Cell Responses?
Should We Treat Chronic Hepatitis C in HIV with Peginterferon Alpha 2a or 2b?
A Third Pathogenic and Lymphotropic Human Retrovirus
Hepatitis in the New IAS-USA Panel Antiretroviral Treatment Guidelines
Prompt Arrival of Antivirals against Hepatitis C for HIV Patients
Pre-Exposure Prophylaxis for HIV Upfront
Gene Therapy Towards HIV Cure
News from the 2011 Coinfection Workshop
Rosuvastatin – The Most Potent and Less Toxic Statin for HIV Patients
Cancer in HIV Patients